Crossmark

Evaluation of clinical events and costs associated with the addition of dapagliflozin to chronic kidney disease treatment: Cost offset analysis

Crossref DOI link: https://doi.org/10.1016/j.nefroe.2024.11.020

Published Print: 2024-11

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Navarro-González, Juan Francisco

Ortiz, Alberto

Cebrián Cuenca, Ana

Segú, Lluís

Pimentel, Belén

Aranda, Unai

Lopez-Chicheri, Blanca

Capel, Margarita

Pomares Mallol, Elisenda

Caudron, Christian

García Sánchez, Juan José

Alcázar Arroyo, Roberto
Funding

Funding for this research was provided by:

European Regional Development Fund (101101220)

AstraZeneca

European Commission

Instituto de Salud Carlos III (RD21/0005/0001, RD21/0005/0013)
License Information

Text and Data Mining valid from 2024-11-01

Text and Data Mining valid from 2024-11-01

Version of Record valid from 2024-11-30
More Information

This article is maintained by: Elsevier

Article Title: Evaluation of clinical events and costs associated with the addition of dapagliflozin to chronic kidney disease treatment: Cost offset analysis

Journal Title: Nefrología (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.nefroe.2024.11.020

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.nefro.2024.05.010

Content Type: article

Copyright: © 2024 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U.